Vaccine Manufacturing Products and Technologies

Tradition

Vaccines are a group of pharmaceuticals that include some of the oldest biologically-made compounds. The Smallpox vaccine was introduced by Edward Jenner as early as in 1796 and Louis Pasteur created the first live attenuated bacterial (Chicken Cholera) and viral (Rabies) vaccines at the end of the 19th century.

A vaccine contains an antigen that is capable of inducing an immune response in a living organism and as such, typically enhances the organism’s ability to fight off or minimize disease. These antigens can be live attenuated (weakened) microorganisms such as in the MMR (Measles, Mumps, Rubella) virus vaccine, inactivated microbes (bacteria, virus) or parts thereof (proteins, polysaccharides) such as the DTaP (Diphtheria, Tetanus, acellular Pertussis) vaccine. More information on how typical vaccines are manufactured can be found here.

Innovation The vaccine industry has reinvented itself in the past decade by bringing innovation to the traditional manufacturing processes, with New vaccine concepts (recombinant virus & proteins, virus-like-particles, adjuvants) New production technologies (progress in cell culture, optimized purification methods, validated & controlled manufacturing for constant high quality) New visions on facility design (using single-use technologies to eliminate cleaning, enhance asepsis and increase flexibility of the process) Pall's innovative process technologies have been an important contributor to the success of many vaccine production processes, old and new, and we are constantly looking for better solutions for today’s new vaccine development and manufacturing challenges.

Expertise

At Pall, we understand that for the vaccine industry, there is a stringent need to deliver new vaccines fast to the market, at the highest quality, but with a low cost. We work hard to support the vaccine industry’s ability to bring these seemingly opposite manufacturing objectives closer together. Using our EXPERTISE, under the form of products, services and process solutions, you will be able to bring your vaccine faster from development to the market, at an optimized manufacturing cost, with no compromises on the quality.

Learn here more about our:

• Flexible manufacturing platforms
• High Throughput Process development tools
• Confident contaminant control solutions
• Proven product performances
• High quality technical and scientific consulting services

• Sterilizing filtration of adjuvanted vaccines

  Vaccine manufacturers are increasingly using adjuvants to boost the immune response to an antigen. Examples are the pandemic H1N1 vaccines now available in Europe. Issues with sterile filtration can occur, because some products can be difficult to filter and cause premature plugging of filter membranes. In addition, their low surface tension may reduce a filter’s bacterial retention capacity and may lead to a failed bacterial challenge test during validation. Scientists at Pall Life Sciences have been studying these issues and present some recommendations for the selection of filter membranes and sterile filtration process conditions. View more

• Pandemic / seasonal influenza manufacturing

  Pall is working closely with its customers to assist them with the efficient, rapid manufacture of pandemic influenza vaccines. Pall technologies are in use in the production of almost all commercially-available seasonal influenza vaccines. View more